Latest research on Octreotide

Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin.

Latest findings

In eight (44%), there was an excellent correlation (concordance) between disease found on conventional radiology and that found with Octreotide imaging (Figure 1 [source, 2003]
In five patients (28%) conventional radiology showed that disease was more widespread than indicated by Octreotide imaging although this was positive in some areas. [source, 2003]
Four patients (22%) with visible metastatic disease on conventional radiology had negative Octreotide scans. [source, 2003]
In one patient (6%) with bone metastases only, Octreotide scintigraphy demonstrated more extensive involvement compared with conventional radiology including 99mTc bone scintigraphy. [source, 2003]
Imaging with Octreotide does not provide an alternative to conventional radiology in the staging of non-iodine avid thyroid cancer, but may provide additional useful information, particularly in the case of widespread bone metastases. [source, 2003]
It is perhaps not surprising that, if these bone metastases also express somatostatin receptors, Octreotide scintigraphy may prove superior to 99mTc bone scintigraphy. [source, 2003]
Our results compare favourably with other studies that have assessed Octreotide scintigraphy in patients with HCC. [source, 2003]
Two further patients with metastatic HCC had metastases visualised by Octreotide scintigraphy (Tisell ). [source, 2003]
The Octreotide scans were compared to FDG-PET scans and found to be slightly inferior. [source, 2003]
A major advantage of scintigraphy using Octreotide compared to radioiodine is that patients do not have to withdraw thyroid hormone. [source, 2003]